Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway

Cell Death and Disease

Volumn 6, Issue 6, 2015, Pages

  Namba, T ^a   Kodama, R ^a   Moritomo, S ^b   Hoshino, T ^c   Mizushima, T ^c  

^a KOCHI UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA SMOOTH MUSCLE ACTIN; DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GANCICLOVIR; GEMCITABINE; GLYCOGEN SYNTHASE KINASE 3BETA; LAMIVUDINE; LOPERAMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROMETHAZINE; PROTEIN KINASE B; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; SMAD3 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; VALACICLOVIR; VIDARABINE; ZIDOVUDINE; ANTINEOPLASTIC ANTIMETABOLITE; ANTIVIRUS AGENT; DEOXYCYTIDINE; GLYCOGEN SYNTHASE KINASE 3; GSK3B PROTEIN, HUMAN; GSK3B PROTEIN, MOUSE; SLC29A1 PROTEIN, HUMAN; SMALL INTERFERING RNA; SNAI1 PROTEIN, HUMAN; SNAI1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CANCER RESISTANCE; CANCER THERAPY; CLINICAL MEDICINE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG SENSITIZATION; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCREENING TEST; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; NUDE MOUSE; PANCREATIC NEOPLASMS; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTIVIRAL AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZIDOVUDINE;

EID: 84989344362     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.172     Document Type: Article

References (49)

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617.
2. Lennon AM, Wolfgang CL, Canto MI, Klein AP, Herman JM, Goggins M et al. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res 2014; 74: 3381-3389.
3. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
4. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277.
5. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
6. Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T et al. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial-SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol 2008; 26: 3695-3701.
7. Goncalves A, Gilabert M, Francois E, Dahan L, Perrier H, Lamy R et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 2012; 23: 2799-2805.
8. Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012; 13: 181-188.
9. Kindler HL, Ioka T, Richel DJ, Bennouna J, Letourneau R, Okusaka T et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011; 12: 256-262.
10. King AE, Ackley MA, Cass CE, Young JD, Baldwin SA. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci 2006; 27: 416-425.
11. Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D et al. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest 2014; 124: 1525-1536.
12. Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst 2014; 106: djt347.
13. Marechal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012; 143: 664-674 e661-666.
14. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820-5828.
15. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS et al. Acquisition of epithelialmesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009; 69: 2400-2407.
16. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 2011; 8: 27-33.
17. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
18. Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 2013; 27: 2192-2206.
19. Mitsuya H, Weinhold KJ, Furman PA St, Clair MH, Lehrman SN, Gallo RC et al. 3'-Azido-3'deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985; 82: 7096-7100.
20. Datta A, Bellon M, Sinha-Datta U, Bazarbachi A, Lepelletier Y, Canioni D et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 2006; 108: 1021-1029.
21. Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009; 113: 6528-6532.
22. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 2003; 9: 5000-5008.
23. Perez-Torras S, Garcia-Manteiga J, Mercade E, Casado FJ, Carbo N, Pastor-Anglada M et al. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. Biochem Pharmacol 2008; 76: 322-329.
24. Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005; 65: 9510-9516.
25. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004; 23: 1539-1548.
26. Kramer N, Walzl A, Unger C, Rosner M, Krupitza G, Hengstschlager M et al. In vitro cell migration and invasion assays. Mutat Res 2013; 752: 10-24.
27. Nieto MA The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002; 3: 155-166.
28. Vega S, Morales AV, Ocana OH, Valdes F, Fabregat I, Nieto MA. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 2004; 18: 1131-1143.
29. Zhu LF, Hu Y, Yang CC, Xu XH, Ning TY, Wang ZL et al. Snail overexpression induces an epithelial to mesenchymal transition and cancer stem cell-like properties in SCC9 cells. Lab Invest 2012; 92: 744-752.
30. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004; 6: 931-940.
31. Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem 2003; 278: 21113-21123.
32. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007; 14: 3629-3637.
33. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24: 4731-4737.
34. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007; 67: 3853-3861.
35. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabineinduced cell death. Oncogene 2003; 22: 3243-3251.
36. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N, Marchesini M et al. Oncogene ablationresistant pancreatic cancer cells depend on mitochondrial function. Nature 2014; 514: 628-632.
37. Montero TD, Racordon D, Bravo L, Owen GI, Bronfman ML, Leisewitz AV. PPARalpha and PPARgamma regulate the nucleoside transporter hENT1. Biochem Biophys Res Commun 2012; 419: 405-411.
38. Soler C, Felipe A, Casado FJ, Celada A, Pastor-Anglada M. Nitric oxide regulates nucleoside transport in activated B lymphocytes. J Leukoc Biol 2000; 67: 345-349.
39. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-337.
40. Maseki S, Ijichi K, Tanaka H, Fujii M, Hasegawa Y, Ogawa T et al. Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3beta/snail signalling pathway. Br J Cancer 2012; 106: 1196-1204.
41. Miething C, Scuoppo C, Bosbach B, Appelmann I, Nakitandwe J, Ma J et al. PTEN action in leukaemia dictated by the tissue microenvironment. Nature 2014; 510: 402-406.
42. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000; 60: 5451-5455.
43. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9: 1956-1967.
44. Namba T, Tian F, Chu K, Hwang SY, Yoon KW, Byun S et al. CDIP1-BAP31 complex transduces apoptotic signals from endoplasmic reticulum to mitochondria under endoplasmic reticulum stress. Cell Rep 2013; 5: 331-339.
45. Namba T, Hoshino T, Suemasu S, Takarada-Iemata M, Hori O, Nakagata N et al. Suppression of expression of endoplasmic reticulum chaperones by Helicobacter pylori and its role in exacerbation of non-steroidal anti-inflammatory drug-induced gastric lesions. J Biol Chem 2010; 285: 37302-37313.
46. Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res 2006; 66: 5338-5345.
47. Guillen-Gomez E, Pinilla-Macua I, Perez-Torras S, Choi DS, Arce Y, Ballarin JA et al. New role of the human equilibrative nucleoside transporter 1 (hENT1) in epithelial-to-mesenchymal transition in renal tubular cells. J Cell Physiol 2012; 227: 1521-1528.
48. Mima S, Tsutsumi S, Ushijima H, Takeda M, Fukuda I, Yokomizo K et al. Induction of claudin4 by nonsteroidal anti-inflammatory drugs and its contribution to their chemopreventive effect. Cancer Res 2005; 65: 1868-1876.
49. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9: 671-675.